Information Provided By: 
Fly News Breaks for October 22, 2018
AVEO
Oct 22, 2018 | 11:04 EDT
Piper Jaffray analyst Edward Tenthoff believes the data for tivozanib combined with Opdivo to treat metastatic renal cell carcinoma presented at the ESMO meeting competitively position Aveo Pharmaceuticals as the treatment landscape for front-line RCC moves to I-O and TKI combinations. An ORR of 56% and DCR of 96% represent "promising early activity," said Tenthoff., who reiterates his Overweight rating and $5 target on Aveo shares.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
